Genomes and Genes
Michael B Lilly
Affiliation: University of California
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMatthew R Janes
Department of Molecular Biology and Biochemistry, Institute for Immunology, University of California Irvine, Irvine, California, USA
Nat Med 16:205-13. 2010..These findings establish that Ph(+) transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy...
- Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CMLMarie P Shieh
Division of Hematology Oncology, Department of Medicine, and Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA
Clin Med Insights Oncol 5:185-99. 2011..Therapy selection will depend on both clinical and molecular factors, which we will discuss in this review...
- Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75Melanie Mediavilla-Varela
Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
Mol Cancer 8:68. 2009..This knowledge is important for circumventing HRPC chemoresistance and reducing disparities in prostate cancer mortality...
- Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyMichael B Lilly
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, USA
Am J Hematol 85:164-70. 2010..Compared with the 70 mg twice daily, dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL. (clinicaltrials.gov identifier: NCT00123487)...
- Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteinsKimberly Romero Rosales
Department of Developmental and Cell Biology, University of California, Irvine, CA 92697, USA
Biochem J 439:299-311. 2011....
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas
Department of Molecular Biology and Biochemistry, Center for Immunology, University of California, Irvine, Irvine, California, USA
J Clin Invest 118:3038-50. 2008..Our findings provide mechanistic insights into PI3K dependency in oncogenic networks and provide a rationale for targeting class IA PI3K, alone or together with mTOR, in the treatment of Ph+ ALL...